Recent News

• 03.31.2026 - Diabetes patients CURED of disease with groundbreaking new treatment, study shows
• 03.24.2026 - Eledon unveils new type 1 diabetes data
• 03.24.2026 - Tegoprubart enables insulin independence in type 1 diabetes islet transplant study
• 03.24.2026 - Breaking down the kidney transplant landscape on National Donor Day
• 02.24.2026 - Arkansas woman participates in clinical trial to cure type one diabetes
• 02.23.2026 - Tegoprubart is a Game Changer in Islet Cell Transplantation Surgery for T1D Patients
• 02.06.2026 - Scrip Asks… What Does 2026 Hold for Biopharma? Part 4: R&D Innovation
• 02.06.2026 - Targeting Costimulatory Pathways in Kidney Transplant With Eliezer Katz, MD
• 02.06.2026 - 2-Year Phase 1b Tegoprubart Preserves Kidney Function in Transplant Recipients, With Eliezer Katz, MD
• 01.20.2026 - From pig to patient: Pioneering transplants from pigs to humans could mark a turning point for organ replacement.

Recent Filings

• 03.26.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.19.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.19.2026 - EX-99.1 EX-99.1
• 03.19.2026 - 8-K Current report
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.13.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.21.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.16.2026 - 4 Statement of changes in beneficial ownership of securities